Radiation toxicity in prostate cancer patients

Prostate cancer (PC) is the most frequent male tumor, accounting for about one-third of all cancers in men. Since survival is often favorable regardless of therapy, treatment decisions may depend on therapy-specific health outcomes. The majority of men initially diagnosed with localized PC ultimatel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stanić Jelena, Stanković Vesna, Nikitović Marina
Formato:	article
Lenguaje:	EN SR
Publicado:	University of Belgrade, Medical Faculty 2021
Materias:	prostate cancer radiotherapy radiation toxicity Medicine R
Acceso en línea:	https://doaj.org/article/c3375963149d43a698328be0a680a7ec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3375963149d43a698328be0a680a7ec
record_format	dspace
spelling	oai:doaj.org-article:c3375963149d43a698328be0a680a7ec2021-12-05T21:26:44ZRadiation toxicity in prostate cancer patients0369-15272466-552510.5937/mp72-32377https://doaj.org/article/c3375963149d43a698328be0a680a7ec2021-01-01T00:00:00Zhttps://scindeks-clanci.ceon.rs/data/pdf/0369-1527/2021/0369-15272102026S.pdfhttps://doaj.org/toc/0369-1527https://doaj.org/toc/2466-5525Prostate cancer (PC) is the most frequent male tumor, accounting for about one-third of all cancers in men. Since survival is often favorable regardless of therapy, treatment decisions may depend on therapy-specific health outcomes. The majority of men initially diagnosed with localized PC ultimately die with, rather than of, their disease. As a result, men who are diagnosed will live many years with the treatment's sequelae. The major therapeutic strategies include radical prostatectomy or external beam radiotherapy. Radiotherapy is one of the curative treatment options. The tumor dose-response relationship has been studied and is widely accepted. The unsatisfactory local control with doses < 70 Gy led to dose escalation using highly precise radiotherapy techniques - three-dimensional conformal radiotherapy and intensity-modulated radiotherapy enabling the delivery of high radiation doses up to 74 - 78 Gy. Bowel, rectal and urinary toxicities are the principal limiting factors in delivering a high dose. Acute symptoms include a change in bowel habits, urgency, and fecal incontinence. The most commonly reported late toxicities were chronic diarrhea, proctitis, or rectal bleeding. Several factors have been associated with increased gastrointestinal toxicity such as larger bowel volume receiving high doses, the patient's age, diabetes, and concomitant use of androgen deprivation therapy. Bladder damage resulting from acute radiation toxicity is manifested as radiation cystitis (frequent urination and dysuric disorders). Smoking, previous abdominopelvic surgeries and the use of diuretics significantly affect the occurrence of acute genitourinary toxicity grade ≥ 2. Risk factors for the development of late genitourinary complications are higher radiation dose, previous urinary problems, transurethral interventions, and acute genitourinary complications. It is essential to strike a balance between the therapeutic benefits and radiotherapy side effects. Severe late complications significantly reduce the quality of life (QOL) of PC survivors. Early detection and proper evaluation of complications are especially important in increasing the patient's QOL.Stanić JelenaStanković VesnaNikitović MarinaUniversity of Belgrade, Medical Facultyarticleprostate cancerradiotherapyradiation toxicityMedicineRENSRMedicinski Podmladak, Vol 72, Iss 2, Pp 26-33 (2021)
institution	DOAJ
collection	DOAJ
language	EN SR
topic	prostate cancer radiotherapy radiation toxicity Medicine R
spellingShingle	prostate cancer radiotherapy radiation toxicity Medicine R Stanić Jelena Stanković Vesna Nikitović Marina Radiation toxicity in prostate cancer patients
description	Prostate cancer (PC) is the most frequent male tumor, accounting for about one-third of all cancers in men. Since survival is often favorable regardless of therapy, treatment decisions may depend on therapy-specific health outcomes. The majority of men initially diagnosed with localized PC ultimately die with, rather than of, their disease. As a result, men who are diagnosed will live many years with the treatment's sequelae. The major therapeutic strategies include radical prostatectomy or external beam radiotherapy. Radiotherapy is one of the curative treatment options. The tumor dose-response relationship has been studied and is widely accepted. The unsatisfactory local control with doses < 70 Gy led to dose escalation using highly precise radiotherapy techniques - three-dimensional conformal radiotherapy and intensity-modulated radiotherapy enabling the delivery of high radiation doses up to 74 - 78 Gy. Bowel, rectal and urinary toxicities are the principal limiting factors in delivering a high dose. Acute symptoms include a change in bowel habits, urgency, and fecal incontinence. The most commonly reported late toxicities were chronic diarrhea, proctitis, or rectal bleeding. Several factors have been associated with increased gastrointestinal toxicity such as larger bowel volume receiving high doses, the patient's age, diabetes, and concomitant use of androgen deprivation therapy. Bladder damage resulting from acute radiation toxicity is manifested as radiation cystitis (frequent urination and dysuric disorders). Smoking, previous abdominopelvic surgeries and the use of diuretics significantly affect the occurrence of acute genitourinary toxicity grade ≥ 2. Risk factors for the development of late genitourinary complications are higher radiation dose, previous urinary problems, transurethral interventions, and acute genitourinary complications. It is essential to strike a balance between the therapeutic benefits and radiotherapy side effects. Severe late complications significantly reduce the quality of life (QOL) of PC survivors. Early detection and proper evaluation of complications are especially important in increasing the patient's QOL.
format	article
author	Stanić Jelena Stanković Vesna Nikitović Marina
author_facet	Stanić Jelena Stanković Vesna Nikitović Marina
author_sort	Stanić Jelena
title	Radiation toxicity in prostate cancer patients
title_short	Radiation toxicity in prostate cancer patients
title_full	Radiation toxicity in prostate cancer patients
title_fullStr	Radiation toxicity in prostate cancer patients
title_full_unstemmed	Radiation toxicity in prostate cancer patients
title_sort	radiation toxicity in prostate cancer patients
publisher	University of Belgrade, Medical Faculty
publishDate	2021
url	https://doaj.org/article/c3375963149d43a698328be0a680a7ec
work_keys_str_mv	AT stanicjelena radiationtoxicityinprostatecancerpatients AT stankovicvesna radiationtoxicityinprostatecancerpatients AT nikitovicmarina radiationtoxicityinprostatecancerpatients
_version_	1718371029365030912

Radiation toxicity in prostate cancer patients

Ejemplares similares